Asset Details
Do you wish to reserve the book?
Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease
Do you wish to request the book?
Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease
2025
Overview
INTRODUCTION The cholinergic basal forebrain system, particularly the nucleus basalis of Meynert (Ch4), is selectively vulnerable to amyloid beta (Aβ) and tau in Alzheimer's disease (AD). Their interplay may be a critical driver of AD progression, but remains poorly understood. METHODS Data from 779 older individuals in the Australian Imaging, Biomarker, and Lifestyle study were analyzed, all of whom underwent 18F‐NAV4694 Aβ and 18F‐MK6240 tau positron emission tomography and magnetic resonance imaging. RESULTS The co‐occurrence of Aβ and mesial‐temporal (MTL) tau pathologies was associated with reduced Ch4 volumes in cognitively unimpaired individuals. MTL tau burden was associated with Ch4 volumes exclusively in cognitively unimpaired individuals with established Aβ pathology, which was not observed for the hippocampus. This association persists in individuals with mild cognitive impairment, but was not apparent in AD dementia. DISCUSSION Findings underscore early Ch4 degeneration associated with Aβ and tau pathologies, supporting potential cognitive benefits of cholinergic therapies in early disease stages. HIGHLIGHTS Early‐stage tau pathology in the mesial‐temporal (MTL) region was assessed using 18F‐MK6240 positron emission tomography. Co‐occurring amyloid beta and MTL tau was linked to reduced nucleus basalis of Meynert (Ch4) volume in cognitively unimpaired individuals. Ch4 volume was associated with MTL tau burden exclusively in preclinical Alzheimer's disease (AD). No comparable association was observed between MTL tau and hippocampal volume. The MTL tau–Ch4 association persisted into the prodromal stage of AD.
Publisher
John Wiley & Sons, Inc
Subject
/ Aged
/ Alzheimer Disease - diagnostic imaging
/ Alzheimer Disease - metabolism
/ Alzheimer Disease - pathology
/ Amyloid beta-Peptides - metabolism
/ Atrophy
/ Basal Forebrain - diagnostic imaging
/ Basal Forebrain - metabolism
/ Basal Nucleus of Meynert - diagnostic imaging
/ Basal Nucleus of Meynert - pathology
/ Cognitive Dysfunction - diagnostic imaging
/ Cognitive Dysfunction - pathology
/ Dementia
/ Disease
/ Female
/ Humans
/ Male
/ Positron emission tomography
/ Positron emission tomography (PET)
/ Temporal Lobe - diagnostic imaging
/ Time
